期刊名称：JOURNAL OF DIABETES ISSN： 1753-0393 出版频率： Monthly 出版社： WILEY, 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774   出版社网址： http://as.wiley.com/WileyCDA/Brand/id-35.html 期刊网址： http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1753-0407 影响因子： 4.006 主题范畴： ENDOCRINOLOGY & METABOLISM;    China Journals 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Journal of Diabetes © Wiley Publishing Asia Pty Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine Edited By: Zachary T. Bloomgarden and Guang Ning Impact Factor: 2.939 ISI Journal Citation Reports © Ranking: 2012: 55/122 (Endocrinology & Metabolism) Online ISSN: 1753-0407, ISSN: 1753-0393 Society Information Published in association with Ruijin Hospital, Shanghai JiaoTong University School of Medicine An official journal of the Chinese Society of Endocrinology Endorsed by the Chinese Endocrinologist Association   Editor Conflict Guidelines Conflict of Interest Policy for Editors of the Journal of Diabetes The Editors of the Journal of Diabetes recognize that fairness is critical to the process by which medical information is conveyed. The Journal therefore follows the recommendations of the International Committee of Medical Journal Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication" 1. At the same time, we are concerned that many policies ostensibly established for transparency have taken positions antagonistic to what should, and typically is, a mutually beneficial interaction between scientists, physicians, researchers and industry, and we support the (slightly modified) statement of the American Association of Clinical Endocrinologists and the American College of Endocrinology which observes, “There is no inherent conflict of interest in the working relationship of scientists, physicians, researchers with industry and government. Rather, there is a commonality of interest that is healthy, desirable, and beneficial.” 2. The Editors have been influenced in preparing this statement by the Conflict of Interest Policy for Editors of Obesity 3. The author guidelines of the Journal of Diabetes require authors to disclose financial and personal interests which might be relevant to the topics of their manuscripts, and the Editors have similar expectations of reviewers, who shall acknowledge any potential such interests and, if there is any question, shall discuss with the editors whether these might interfere with their ability to objectively review a manuscript. The Journal editors will disclose, on the journal's Web site (wileyonlinelibrary.com/journal/jdb), all financial relationships relevant to the fields of medicine and biology for themselves, their spouses, and their dependent children outside of compensation related to their employment, including ownership of stocks or bonds, participation in speaker bureaus, advisory boards, or consultations, and support for research or educational activities, during the prior 12 months. Editors will not review or take responsibility for manuscripts submitted by former students, fellows, mentors, collaborators, and other associates with whom they have worked in the previous 5 years and by faculty members at their own institutions. Manuscripts submitted to the Journal by one of the editors will be handled by another editor. REFERENCES 1. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication <http://www.icmje.org> (February 2006). Accessed 8 May 2007. 2. AACE Position Statement on Physician/Industry Relationships, downloaded September 7, 2009 from http://media.aace.com/article_display.cfm?article_id=4929 3. Conflict of Interest Policy for Editors of Obesity, downloaded September 7, 2009 from http://www.nature.com/oby/journal/v17/n9/full/oby2009215a.html Editors’ disclosure statements Editors-in-Chief Zachary Bloomgarden, MD Speakers Bureau: Glaxo SmithKline, Merck, NovoNordisk, Lilly, Amylin, Daichi Sankyo. Advisory Panel: Medtronics, Takeda, Merck, AtheroGenics, Inc., CV Therapeutics, Sankyo, BMS, AstraZeneca, Boehringer Ingelheim. Consultant: Merck, Novartis, Daichi Sankyo, Dainippon Sumitomo Pharma America, Forest Laboratories, Nastech. Stock ⁄Shareholder: Alcon, Bard, Edwards Lifesciences, Merck, NovoNordisk, Novartis, Roche, Stryker, Thermo Fisher Scientific. Guang Ning, MD, PhD Nothing to declare Associate Editors Andrew Drexler, MD. FACE Nothing to declare You-Fei Guan, MD, PhD Consultant: ChemPartner Grant ⁄ Research support: Lilly and AstraZeneca Yehuda Handelsman MD, FACP, FACE Speakers Bureau: AstraZeneca-Lipids; Daiichi-Sankyo-DM, Lipids; HTN GlaxoSmithKline- DM, Lipids; Merck- DM; Novartis- HTN. Consultant: Daiichi Sankyo US- DM, Lipids; GSK- DM, lipids; Merck- DM, Obesity; Minimed- DM; XOMA- IR; Thetys- Pre-DM. Grant/Research support- Daiichi Sankyo US- DM, Lipids; GSK- DM; Novartis- HTN; NovoNordix - DM; Takeda- DM; Sanofiaventis- DM. Xiao-Ying Li, MD, PhD Nothing to declare Jian-Min Liu, MD, PhD Nothing to declare News FIRST Impact Factor Now Released 2.939! Read, cite the journal, or submit your paper to keep contributing to the success of Journal of Diabetes. Click here to access the TOP cited articles published in 2011-2012. Call for Papers: Comparative Effectiveness Research on Diabetes As defined by the Institute of Medicine, Comparative Effectiveness Research(CER) aims to generate and synthesize evidence comparing the benefits and harms of alternative methods to prevent, diagnose, treat and monitor a clinical condition, or to improve the delivery of care. The proposal to include $1.1 billion for Comparative Effectiveness Research in the US federal stimulus package initiated much discussion and debate. The Journal of Diabetes will engage in the exploration of CER in diabetes, and invites submissions. Topics of interest include – but are not limited to: the complex interactions between biological, psychological, and behavioral factors of care, and the comparison of new diabetes drugs and agents with existing therapies, in the endeavor to reduce the health and economic burdens of diabetes mellitus. Studies recently reported which address aspects of CER have addressed goals of glycemic, lipid, and blood pressure treatment in persons with diabetes; and comparisons of specific therapeutic approaches for glucose-lowering in type 2 diabetes, both with parenteral and with oral medications; The submitted manuscripts will undergo a speedy peer review process. Authors should follow the requirement of Author Guidelines. Please submit your work online at: http://mc.manuscriptcentral.com/jdb Accepted submissions will be published in a special section of the Journal of Diabetes, and will be freely accessible. Young Clinician Investigator Award To celebrate the successful launch of Journal of Diabetes, the Editors are announcing the Young Clinician Investigator Award. The Award recognizes outstanding excellence in research and practice contributed to the field of diabetes by a young investigator. The Young Clinician Investigator Award offers a number of unique benefits to support the young group leader in establishing a reputation as an excellent scientist. One awardee will be named by the Editorial Board of the journal, and will be honored at 2011 Annual Meeting of Chinese Society of Endocrinology. The Award • A cash award of 2000 USD • A 1000 USD contribution to a round trip economy ticket to attend the 2011 Annual Meeting of Chinese Society of Endocrinology (this cannot be redeemed for cash) • An Oral Presentation of the awardee’s work at the 2011 Annual Meeting of Chinese Society of Endocrinology • One year complimentary online subscription to Journal of Diabetes in 2012 Eligibility Any student, resident, fellow or junior faculty is eligible for the Young Clinician Investigator Award. The applicant must: • Be the first author of an original article submitted to Journal of Diabetes • Be no more than 35 years old at the time of submission • Be a MD student or equivalent or must have graduated less than 3 years previously • Be directly responsible for the majority of the work presented Criteria for Evaluation • The winner will be evaluated on the scientific merit and originality of the clinical relevant research • Only authors of original articles will be considered • The choice will be made by the journal’s Editorial Board, whose decision will be final Procedure • All manuscripts must be submitted through http://mc.manuscriptcentral.com/jdb. No other route of submission will be accepted • State clearly in the cover letter that the first author would like to compete for this award • Provide a short author biography, and submit with the application Deadline The manuscripts must be submitted no later than 24:00(GMT) of June 1, 2012 Enquiry Email: editor@jdiabetes.com Study Design Support It is a free and confidential service by the editorial team at Journal of Diabetes to help you design your studies. Download the full introduction here HOW DOES IT WORK? Our editorial team provides you with free and confidential feedback on your study design before you submit your final study to a journal, or before you do the study. Study Design Support does not reject, accept or publish your study design. We just provide you with free and confidential feedback. You submit your study design to us, using a submission form. HOW DO I SUBMIT? Please download the submission form and submit it to editor@jdiabetes.com Overview Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Journal of Diabetes editorial team now offer editorial feedback at a much earlier stage in the publishing process. Researchers can submit study designs without results for early feedback. This feedback can be confidential or available for public view based on the choice of the researchers. Journal of Diabetes Forum helps researchers and encourages discussion and learning among peers. Click here for more information on this exciting new service. Aims and Scope Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Journal has established a specific "Asia Track" to further this endeavor by bringing to the international community articles which focus on aspects of diabetes of particular relevance to Asia. The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and will solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content. Readership Clinical doctors and researchers in diabetes Keywords diabetes, research, therapeutics, endocrinology, epidemiology, pathogenesis, prevention Abstracting and Indexing Information Abstracts on Hygiene & Communicable Diseases (CABI) Academic Search (EBSCO Publishing) Agroforestry Abstracts (CABI) CAB Abstracts® (CABI) CAS: Chemical Abstracts Service (ACS) Crop Physiology Abstracts (CABI) Current Contents: Clinical Medicine (Thomson Reuters) Forest Products Abstracts (CABI) Forestry Abstracts (CABI) Global Health (CABI) Leisure, Recreation & Tourism Abstracts (CABI) MEDLINE (NLM) Nutrition Abstracts & Reviews Series A: Human & Experimental (CABI) Plant Breeding Abstracts (CABI) Plant Genetic Resources Abstracts (CABI) Review of Aromatic & Medicinal Plants (CABI) Rural Development Abstracts (CABI) Science Citation Index Expanded (Thomson Reuters) SCOPUS (Elsevier) Soybean Abstracts Online (CABI) Tropical Diseases Bulletin (CABI) Web of Science (Thomson Reuters)   Instructions to Authors Author Guidelines To find out how to prepare your manuscript, please click on Authors Guidelines. Submit Online If you are ready to submit an article, please click on Online Submission. Complete instructions for preparing and submitting manuscripts online are provided at the online submission site. For online help and tutorials on how to use the online submission site, please click on Help. Author Services Author Services enables authors to track their article, once it has been accepted, through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production so they do not need to contact the Production Editor to check on progress. Visit http://authorservices.wiley.com for more details on online production tracking and for a wealth of resources, including FAQs and tips on article preparation, submission, our editorial policies, your rights as an author, copyright matters and more. Early View Journal of Diabetes is covered by Wiley Blackwell Publishing's Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors‟ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found at http://www.doi.org/faq.html Offprints A minimum of 50 offprints will be provided upon request, at the author’s expense. These paper offprints may be ordered online. Please visit http://offprint.cosprinters.com/, fill in the necessary details and ensure that you type information in all of the required fields. If you have queries about offprints, please email offprint@cosprinters.com. Study Design Support Free and confidential service by the editorial team at Journal of Diabetes HOW DOES IT WORK? Our editorial team provides you with free and confidential feedback on your study design before you submit your final study to a journal, or before you do the study. Study Design Support does not reject, accept or publish your study design. We just provide you with free and confidential feedback. You submit your study design to us, using a submission form. WHAT IS THE ADVANTAGE? How many times have you or will you submit a manuscript to a journal and receive requests for major revisions or rejection that are both surprising and delay your work several weeks or months? Study Design Support is an opportunity for you to get early feedback that could prove critical for your final manuscript to qualify for timely acceptance in journal peer review. For more information about this service, click here, which is a PDF file, you may need to install Adobe Acrobat Reader on your computer first. Thank you for your submission! Please do not hesitate to contact us if you have any questions. Editorial Correspondence: Ms Imelda LEE Editorial Assistant, Journal of Diabetes 15th Floor, Building #11, Ruijin Hospital, 197 Ruijin Er Road Shanghai 200025, China Email: editor@jdiabetes.com Tel: 86 21 6437 0045 extn 610915 Fax: 86 21 64151361 Instructions to Authors J_Diabetes_Author_Guidelines.pdf Editorial Board Editors-in-Chief Zachary T. Bloomgarden, USA Guang Ning, China Associate Editors: Andrew J. DREXLER, USA Daniel EINHORN, USA George GRUNBERGER, USA You-Fei GUAN, China Yehuda HANDELSMAN, USA Xiao-Ying LI, China Jian-Min LIU, China Wei-Qing WANG, China Jian-Ping WENG, China Editorial Board: Yufang BI, China Lu CAI, USA Juliana C. CHAN, Hong Kong, China Lulu CHEN, China Yan CHEN, China Jean Louis CHIASSON, Canada Paresh DANDONA, USA Jaime A. DAVIDSON, USA Hong-Kui DENG, China Earl S. FORD, USA Philippe FROGUEL, UK Hertzel C. GERSTEIN, Canada Steven M. HAFFNER, USA Jie HONG, China Rachel HUXLEY, Australia Sun Hua JEE, Korea Li-Nong JI, China Wei-Ping JIA, China Takashi KADOWAKI, Japan Hideaki KANETO, Japan Dong Chon KANG, Japan Tai Hing LAM, Hong Kong, China Xu LIN, China Peter LITTLE, Australia Feng LIU, USA Jun-Li LIU, Canada S.V. MADHU, India Shinichi MATSUMOTO, Japan Yuji MATSUZAWA, Japan Anoop MISRA, India Changyu PAN, China Anuska PATEL, Australia Leonid PORETSKY, USA Marc PRENTKI, Canada Robert RAPAPORT, USA Basil D. ROUFOGALIS, Australia Jonathan E. SHAW, Australia Iichiro SHIMOMURA, Japan Gerald I. SHULMAN, USA Jay SKYLER, USA Haoming TIAN, China Paul M. VANHOUTTE, Hong Kong, China Angela Yee-Moon WANG, Hong Kong, China Nan-Ping WANG, China Bruce H.R. WOFFENBUTTEL, Netherlands Ai-Min XU, Hong Kong, China Tao XU, China Sho-ichi YAMAGISHI, Japan Gangyi YANG, China Wenying YANG, China M. Temel YILMAZ, Turkey Yi-Hao YU, USA Yi ZHU, China Paul ZIMMET, Australia Dalong ZHU. China Zhiguang ZHOU, China Ming-Hui ZOU, USA Editorial Assistants: Imelda Lee Juan Shi